Humphreys B D, Virginio C, Surprenant A, Rice J, Dubyak G R
Department of Physiology and Biophysics, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106, USA.
Mol Pharmacol. 1998 Jul;54(1):22-32. doi: 10.1124/mol.54.1.22.
1-[N, O-Bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine (KN-62) and N-[1-[N-methyl-p-(5 isoquinolinesulfonyl)benzyl]-2-(4 phenylpiperazine)ethyl]-5-isoquinolinesulfonamide (KN-04) potently inhibit the human lymphocyte P2Z receptor, an ATP-gated cation channel [Br J Pharmacol 120:1483-1490 (1997)]. Although the molecular identity of the lymphocyte P2Z receptor has not been established, it shares many functional characteristics with the cloned P2X7 nucleotide receptor. We have tested whether these isoquinolines inhibit P2X receptor function in human embryonic kidney 293 cells that stably express the human or rat recombinant P2X7 receptors. ATP activation of cation currents and uptake of the organic dye ethidium were potently inhibited by KN-62 and KN-04 in human embryonic kidney cells expressing the human P2X7R but not the rat P2X7R, even though these species homologues share 80% amino acid identity. Introduction of the first 335 amino acids of the human P2X7R sequence conferred KN-62 sensitivity to the rat P2X7R; this suggests that isoquinolines interact with residues in the amino-terminal half (containing the large extracellular loop) of the human P2X7R. KN-62 and KN-04 also potently inhibited ATP-gated Ca2+ influx and ethidium uptake in several leukocyte cell lines (THP-1, BAC1.2f5, and BW5147) that natively express the human or murine P2X7R mRNA. The ability of isoquinoline sulfonamides to potently inhibit human and murine P2X7R signaling will be a useful tool for identifying P2Z/P2X7 functional responses in other cell types. The substantial differences in pharmacological sensitivity between rat and human P2X7R may also indicate structural domains important in channel/pore activation.
1-[N,O-双(5-异喹啉磺酰基)-N-甲基-L-酪氨酰基]-4-苯基哌嗪(KN-62)和N-[1-[N-甲基-p-(5-异喹啉磺酰基)苄基]-2-(4-苯基哌嗪)乙基]-5-异喹啉磺酰胺(KN-04)能有效抑制人淋巴细胞P2Z受体,一种ATP门控阳离子通道[《英国药理学杂志》120:1483 - 1490(1997)]。尽管淋巴细胞P2Z受体的分子身份尚未确定,但它与克隆的P2X7核苷酸受体具有许多功能特征。我们测试了这些异喹啉是否抑制稳定表达人或大鼠重组P2X7受体的人胚肾293细胞中的P2X受体功能。在表达人P2X7R而非大鼠P2X7R的人胚肾细胞中,KN-62和KN-04能有效抑制阳离子电流的ATP激活以及有机染料溴乙锭的摄取,尽管这些物种同源物具有80%的氨基酸同一性。导入人P2X7R序列的前335个氨基酸赋予大鼠P2X7R对KN-62的敏感性;这表明异喹啉与人类P2X7R氨基末端一半(包含大的细胞外环)中的残基相互作用。KN-62和KN-04还能有效抑制几种天然表达人或小鼠P2X7R mRNA的白细胞系(THP-1、BAC1.2f5和BW5147)中的ATP门控Ca2+内流和溴乙锭摄取。异喹啉磺酰胺有效抑制人和小鼠P2X7R信号传导的能力将成为识别其他细胞类型中P2Z/P2X7功能反应的有用工具。大鼠和人P2X7R之间药理学敏感性的显著差异也可能表明在通道/孔激活中重要的结构域。